Consistent with these data, studies in clinical trials have shown that IL1β signaling blockade using anakinra (recombinant human IL1 receptor antagonist) leads to improvement in type-2 diabetes (T2D) and inflammation13. This evidence concerns the gene IL1B and type 2 diabetes mellitus.